# PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies

> **NCT00611793** · PHASE1 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 50 (estimated)

## Conditions studied

- Refractory Malignancy
- Advanced Malignancies

## Interventions

- **DRUG:** PTK787/ZK222584 and Bevacizumab

## Key facts

- **NCT ID:** NCT00611793
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2008-01
- **Final completion:** 2009-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2009-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00611793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00611793, "PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00611793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*